恶性胸膜间皮瘤15例临床分析

回顾性分析1991年7月-2001年7月住院的15例胸膜间皮瘤患者的资料，分析患者的病史、临床表现及影像学特点，探讨恶性胸膜间皮瘤的诊断，以减少误诊误治。     

恶性胸膜间皮瘤19例临床分析

目的 经病理证实的19例恶性胸膜间皮瘤的诊断经验。方法 分析19例恶性胸膜间皮瘤的临床资料,包括石棉接触史、临床表现、影像学检查、特殊检查、胸水检测和转移情况,并对比15例手术结果。结果 7例工种与石棉有关,占恶性胸膜间皮瘤36.8%(7/19),18例（94.7%)有胸痛,其中16例（84.2%)伴胸腔积液,1例出现Homer‘s综合症并影响臂丛神经,3例（15.8%)CT下穿刺找到间皮瘤细胞,2例（10.8%)胸水中找到间皮瘤细胞,1例锁髓上淋巴结穿刺找到间皮瘤细胞,15例CT发现胸膜增厚或胸膜上结节样病灶,占恶性弥漫性胸膜间皮瘤78.9%,15例手术病例中11例胸膜广泛增厚或胸壁上广泛不规则大小不等结节融合成片,侵犯肺组织或纵隔胸膜、横膈胸膜。结论 石棉接触史是恶生胸间皮瘤主要病因,胸痛、胸腔积液是胸膜间瘤的主要临床表现,CT对诊断胸膜间皮瘤有重要参考价值。CT下活检能提高诊断率。     

胸膜间皮瘤20例临床分析

目的 总结２０例胸膜间皮瘤的诊治经验,提高对本病的认识,减少误诊率方法 采用回顾性分析法,２０例胸膜间皮瓣的临床资料进行全面分析。结果 ２０例中,中位年龄３９岁,均无石棉接触史。临床表现为胸痛,呼吸困难,胸腔积液。影像学表现为胸膜结节影或带状致密影响。结论 石棉接触史并非胸膜间皮瘤的唯一致病因素。ＣＴ检查对判断病变的范围,程度及对胸部脏器的累及情况优于Ｘ线检查。胸水细胞学检查及ＣＥＡ有助于诊断,但     

胸膜间皮瘤的诊断治疗：附40例报告

作者报告了经病理证实的胸膜间皮瘤４０例。其中良性２例，恶性３８例。３８例恶性者中，有组织学分型１２例，未分型２６例。本组４０例中，３３例切除，３例探查活检，４例未手术。３６例手术，死亡１例，占３％；综合治疗１０例，占３１％。３例探查活检者中，１例术后放疗，１例放疗加化疗，１例无辅助治疗。４例未手术者中，１例未治死亡，２例化疗，１例放疗加化疗。本组有石棉接触史２例，占５％。影像学和细胞学诊断符合率均为５０％（２０／４０）（１１／２２）。１０例失随。生存时间最长者１２年１个月。     

胸膜间皮瘤20例临床分析

目的　总结 2 0例胸膜间皮瘤的诊治经验 ,提高对本病的认识 ,减少误诊率。方法　采用回顾性分析法 ,对 2 0例胸膜间皮瘤的临床资料进行全面分析。结果　 2 0例中 ,中位年龄 39岁 ,均无石棉接触史。临床表现为胸痛、呼吸困难、胸腔积液。影像学表现为胸膜结节影或带状致密影。结论　石棉接触史并非胸膜间皮瘤的唯一致病因素。CT检查对判断病变的范围、程度及对胸部脏器的累及情况优于X线检查。胸水细胞学检查及CEA有助于诊断 ,但确诊仍需活检。局限型无论良恶性均主张手术切除。放疗和腔内化疗可延缓病情。全身化疗疗效不佳     

胸膜间皮瘤的诊治——附11例分析

胸膜间皮瘤的诊治──附１１例分析李红，徐本成胸膜间皮瘤是一种少见的胸膜原发性肿瘤，常易误诊，为提高对本病的认识，现将我院１９９０年２月～１９９５年６月经病理证实的１１例原发性胸膜间皮瘤诊治情况报告如下。临床资料１．一般资料男８例，女３例，年龄２８～７...     

恶性胸膜间皮瘤15例临床分析

回顾性分析 1991年 7月 -2 0 0 1年 7月住院的 15例胸膜间皮瘤患者的资料 ,分析患者的病史、临床表现及影像学特点 ,探讨恶性胸膜间皮瘤的诊断 ,以减少误诊误治     

恶性胸膜间皮瘤12例分析

胸膜间皮瘤为胸膜的原发性肿瘤 ,发病率低 ,误诊率高。肥城市人民医院 1985年 3月～ 1999年 3月共收治恶性胸膜间皮瘤 12例 ,其中 2例误诊为良性疾病。 12例均经病理和细胞学检查证实 ,报告如下。1　临床资料1.1　一般资料本组 12例中 ,男 7例 ,女 5例 ;年龄 16～ 72岁 ,平均年     

胸膜恶性间皮瘤2例

胸膜间皮瘤是发生于胸膜间皮细胞少见的肿瘤。局限性恶性间皮瘤更为少见,该病可累及肺、肋骨、心包膜、膈肌。主要采用手术治疗,报告2例如下:例1.女,20岁。以持续左胸前钝痛2年于1988年5月1日入院。体检:左胸前第6肋肿物隆起6×4.5cm,轻压痛。血沉 30/小时,血胆碱酯酶150IU,胸片:左胸腔实质性阴影10×10cm,第6肋骨破坏3×2cm。术前诊断:左胸壁恶性肿瘤。于1988年5月13日在气管插管静脉内麻醉下行左胸壁肿瘤扩大切除术,距肿物5cm作棱形切口20×10cm,第4肋间进     

胸膜间皮瘤的诊治：附28例分析

胸膜间皮瘤为一少见的原发性胸膜肿瘤,易与肺癌胸膜转移或其他胸膜腔积液混淆。为进一步提高对胸膜间皮瘤的认识,现将我院1980年以来经病理证实的28例原发性胸膜间皮瘤临床诊治情况报告如下。     

Clinical analysis of 19 patients with pleural mesothelioma

Innumber,4173patientswhosufferedfromrespiratorydiseasewerehospitalizedintheDepartmentofRespiratoryMedicinefromJune1992toOctober1997including304patientswithpleuraleffusion.Amongthem,therewere19patientswithpleuralmesotheliloma,whichaccountedfor0.5%ofthetotalor6.2%ofthepatientswithpleuraleffusion.CLINICALDATAGeneraldataAllofthe19caseswerediagnosedwiththoracoscopicbiopsy;13patientsweremales,and6werefemales.Theiragesrangedfrom22to73years,withanaverageof50.8years.Thehistoryoftheirdiseaserang…     

恶性腹膜间皮瘤41例诊治体会

目的 探讨恶性腹膜问皮瘤的临床诊断与治疗方法。方法 对41例外科治疗并经病理证实的恶性腹膜问皮瘤临床资料进行回顾性分析。结果 41例恶性腹膜间皮瘤中,主要临床表现为持续性腹痛者38例(92．7％),腹泻35例(85．4％)。病理类型为上皮样型21例,梭形细胞型11例,混合型9例。21例行CT检查,13例行腹腔镜检查。手术切除率为70．7％,术后行腹腔局部灌注化疗12例(29．3％),全身化疗23例(56．1％),免疫治疗3例(7．3％);全组2年生存率为36．6％。结论 影像学检查是恶性腹膜间皮瘤的主要诊断方法,但肿瘤的确诊须依据病理诊断;恶性腹膜间皮瘤应采用以手术为主的综合治疗方法。     

120例恶性胸膜间皮瘤的临床特征及诊断分析

目的:回顾性分析胸膜间皮瘤患者的临床资料,包括病史、症状、淋巴结及远处脏器转移的规律,并分析不同分期、病理类型及治疗方式的患者生存情况,为该疾病的诊断和治疗提供思路。方法:分析空军军医大学唐都医院2009年4月-2016年9月收治的120例胸膜间皮瘤患者资料,基于第8版TNM分期标准进行肿瘤分期。对不同临床分期、病理类型及治疗方式的患者生存期进行统计分析,应用Kaplan-Meier法进行生存分析。结果:120例患者中有职业暴露史3例(占2.5%)。发病部位为左侧胸膜56例(占46.7%),右侧胸膜63例(占52.5%),双侧胸膜1例。总体的误诊率为30%(36/120),其中误诊为结核32例(26.7%)。以胸痛症状发病55例(占45.8%),胸腔积液107例(占89.2%),两者合并为49例(占40.8%)。确诊方法包括胸膜穿刺诊断53例(占44.2%),胸腔镜诊断41例(占34.2%),开胸探查诊断26例(占21.6%)。所有患者中淋巴结转移(N1~N2)共43例(占35.8%),涉及54个淋巴区;纵隔淋巴结转移42例(占77.8%),纵隔外淋巴区转移12例(占22.2%)。成功随访78例患者,总体中位生存期为15.0个月,1、2、3及5年生存率分别为67.9%、27.7%、16.0%及4.2%。Ⅰ/Ⅱ期患者中位生存期为17.0个月,明显长于Ⅲ/Ⅳ期患者的13.0个月(P<0.05)。上皮型肿瘤患者的中位生存期为17.0个月,与混合型及肉瘤型患者比较有生存优势(P值均<0.05)。手术联合化疗组的患者中位生存期为30.0个月,优于单纯手术、单纯化疗及支持治疗的患者(P值均<0.05)。结论:胸膜间皮瘤的误诊率高,其中大多被误诊为肺结核。恶性胸膜间皮瘤患者主要以胸腔积液症状发病,而且淋巴结转移规律与肺癌有所不同。所以在胸膜间皮瘤的诊断和治疗中,应高度重视这些临床特征,尽量减少误诊,以提高治疗效果。另外,临床分期较早及上皮型病理类型的患者预后相对较好,而且采用手术联合化疗的综合治疗模式可以使胸膜间皮瘤患者获得相对较长的生存期。     

An atypical presentation of thymoma with diffuse pleural dissemination mimicking mesothelioma

Although rare, thymoma is the most frequent type of malignancy in the anterior mediastinum. On most occasions, radiological diagnosis is easy, owing to current imaging studies like computerized tomography. Additionally, the radiological diagnosis of thymoma can be differentiated easily from malignant pleural mesothelioma in most cases. However, thymoma's differentiation from lymphoma, thymic hyperplasia, or thymic remnants sometimes may pose diagnostic challenges. Here, we report a case of advanced thymoma mimicking malignant pleural mesothelioma, with circumferential encasement of the lung. A brief review of the literature with special reference to radiological imaging on thymoma also is presented.     

恶性胸膜间皮瘤15例临床分析

目的:探讨恶性胸膜间皮瘤的临床特点、诊断、治疗和预后。方法:回顾分析我院1994年10月至2005年11月收治的15例恶性胸膜间皮瘤患者的临床资料。结果:恶性胸膜间皮瘤的主要症状为胸闷、气促、咳嗽、胸痛;CT和X线主要表现为胸腔积液、胸膜不规则增厚、肺转移;胸水以渗出液为主,胸水LDH≥500u/L,葡萄糖<3.35mmol/L,血清CEA升高,血清CA125升高;主要依据手术后病检、胸膜穿刺活检、胸水细胞学检查确诊。结论:恶性胸膜间皮瘤以胸闷、胸痛、气促、咳嗽为主要表现,胸膜活检及胸水细胞学为主要确诊方法。有手术机会,多学科综合治疗者,预后较好。     

Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma

Background

Malignant mesothelioma (MM), a primarily asbestos-induced tumour, has a poor prognosis, with over-all 5-year survival less than 5%. Tumour biomarkers are being intensely investigated in MM as aids to diagnosis and prognosis. Hyaluronic acid (HA) is produced in MM but its role in prognostication remains uncertain.

Materials and methods

HA concentrations were determined in matching serum and pleural effusion of 96 MM patients, 26 lung cancer patients and 42 patients with benign effusions resulting from infectious, cardiac, renal, liver and rheumatoid diseases and compared to the current ‘best practice’ biomarker, mesothelin. Liver and kidney function were determined for each patient. Diagnostic accuracy was determined by area under the receiver operator characteristic curve (AUC) analysis following logistic regression modelling. Difference in survival between groups was determined by both log-rank test and Cox proportional hazards regression modelling.

Results

For effusion HA, the AUC (IQ range) was 0.89 (0.82–0.94) and for effusion mesothelin, it was 0.85 (0.78–0.90). Serum HA was not diagnostically useful. A combined measure of effusion HA, and serum and effusion mesothelin had an AUC of 0.92 (0.86–0.96), which was significantly higher than effusion mesothelin alone. Effusion HA had a biphasic distribution in MM patients, dichotomised at a concentration of 75 mg/L. The median survival of MM patients with high effusion HA was 18.0 (13.7–22.4) months, significantly longer than those with low HA effusion levels (12.6 months (8.4–16.8), p = 0.004). Serum HA, and effusion and serum mesothelin were not significant prognostic indicators.

Conclusion

This study demonstrates that a combined biomarker panel has greater diagnostic accuracy than effusion mesothelin alone, and that significant prognostic information is provided by effusion HA.     

Radiotherapy for the treatment of pain in malignant pleural mesothelioma: A systematic review

Radiotherapy is commonly used to treat pain in malignant pleural mesothelioma (MPM). The purpose of this systematic review is to examine the evidence for this practice. Medline (1946–2013), Embase (1974–2013) and Central (The Cochrane Library Issue 9, 2012) databases were searched. Eligible studies met the following criteria: MPM (histological or radiological diagnosis), radiotherapy given with the intent of improving pain, response rates to radiotherapy reported, dose and fractionation reported and the relationship between radiotherapy and pain response explored. All studies had independent review and were graded according to evidence level. Eight studies met the eligibility criteria. Two studies were prospective single arm phase II studies while the remainder were retrospective case series. All were graded as either Level 2 or Level 3 evidence. Due to marked heterogeneity among studies, quantitative synthesis of results was not possible. No high quality evidence currently exists to support radiotherapy in treating pain in MPM. Studies focusing on clear pain endpoints and improving target delineation are needed. Such studies should also use modern radiotherapy techniques and concentrate on dose escalation.     

肺癌患者胸腔积液中CK19 mRNA的转录表达及临床意义

背景与目的 常规细胞学诊断肺癌患者胸腔积液中的癌细胞具有重要的应用价值,然而对胸膜微转移的诊断是有限的.本研究拟探讨CK19 mRNA在肺癌患者胸腔积液中表达的临床意义.方法 应用RT-PCR方法,分别检测86例肺癌患者和40例良性疾病患者胸腔积液中CK19 mRNA的表达,并与常规细胞学诊断进行对比.结果 肺癌组胸腔积液中CK19 mRNA阳性表达率为93.0%(80/86),肺良性疾病组胸腔积液中CK19 mRNA阳性表达率为20.0%(8/40),两组间CK19 mRNA阳性表达率有显著性差异(x2=65.69,P＜0.01).肺癌组胸腔积液中CK19 mRNA阳性表达率与病理类型无关(P＞0.05).检测肺癌患者胸腔积液中的CK19 mRNA,明显优于常规细胞学诊断的敏感性和准确性(P＜0.01).结论 CK19 mRNA可作为检测肺癌患者胸膜微转移的分子标志物,是诊断肺癌患者胸腔积液中脱落癌细胞及其临床分期的重要参考指标.     

恶性胸膜间皮瘤的研究进展

恶性胸膜间皮瘤（MPM）是起源于胸膜间皮细胞的一种恶性肿瘤。MPM的诊断主要依靠胸膜活检与免疫组织化学检查。MPM的治疗应以手术加放疗、化疗、免疫治疗等综合治疗为主。手术治疗的主要术式有胸膜外全肺切除术和胸膜部分剥脱术。放疗以三维适形为主。化疗以顺铂和培美曲塞为标准。免疫治疗的主要靶点有调节性 T 细胞、细胞毒性 T 淋巴细胞相关抗原4、程序性死亡分子1配体等。     

SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma

Background

Malignant mesothelioma is an aggressive, treatment-resistant tumor arising from mesothelium of pleura, peritoneum and pericardium. Despite current combined regimen, its prognosis remains dismal, calling for more effective targeted therapies. We investigated whether aberrant Hh activation may play a role in mesothelioma.

Methods

SMO and SHH expression levels were analyzed in 46 mesothelioma tissue specimens with real-time RT-PCR, and correlation with survival was analyzed with univariate and multivariate Cox proportional hazards models, Kaplan-Meier survival curves, and the log-rank test. We also examined multiple mesothelioma cell lines for SMO expression and the effect of Hh inhibition by a specific SMO antagonist on cell proliferation by MTS assay.

Results

We observed strong correlation between higher SMO and SHH expression levels with poorer overall survival. Remarkably, Hh inhibition by a specific SMO inhibitor significantly suppressed cell proliferation in the mesothelioma cell lines examined.

Conclusion

Our data strongly support that Hh signaling deregulation plays critical roles in proliferation of mesothelioma, and consistently exerts significant impact on prognosis of the disease. Therefore our findings revealed the hitherto unappreciated role of Hh activation in mesothelioma, and pinpointed Hh signaling antagonist as a potential new therapy against this devastating disease.